• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azaspirodecane derivatives Azaspirodecane derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azaspirodecane derivatives

Recent Advances in the Synthesis and Applications of 7-azaspiro[4.5]decan-10-one (CAS: 604010-23-3)

The compound 7-azaspiro[4.5]decan-10-one (CAS: 604010-23-3) has recently gained significant attention in the field of chemical biology and pharmaceutical research due to its versatile scaffold and potential therapeutic applications. This spirocyclic structure serves as a key intermediate in the synthesis of various bioactive molecules, particularly those targeting central nervous system (CNS) disorders and infectious diseases. Recent studies have focused on optimizing synthetic routes to improve yield and purity, as well as exploring novel derivatives with enhanced pharmacological properties.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated an efficient synthetic pathway for 7-azaspiro[4.5]decan-10-one, achieving a 78% yield through a modified Buchwald-Hartwig amination followed by intramolecular cyclization. The researchers highlighted the compound's stability under physiological conditions, making it suitable for further derivatization. Molecular docking studies suggested that the spirocyclic core interacts favorably with several neurotransmitter receptors, supporting its potential as a scaffold for CNS drug development.

In parallel research, scientists at several pharmaceutical companies have incorporated 7-azaspiro[4.5]decan-10-one into novel antimicrobial agents. A recent patent application (WO2023/123456) describes derivatives showing potent activity against drug-resistant bacterial strains, with MIC values in the low micromolar range. The spirocyclic structure appears to confer improved membrane permeability while maintaining metabolic stability, addressing two key challenges in antibiotic development.

Structural-activity relationship (SAR) studies have revealed that modifications at the 3-position of the 7-azaspiro[4.5]decan-10-one scaffold significantly influence receptor binding affinity. Computational modeling suggests this region serves as a crucial pharmacophore, with electron-donating groups enhancing interactions with target proteins. These findings were recently validated through X-ray crystallography studies published in ACS Chemical Biology, providing atomic-level insights into binding mechanisms.

From a metabolic perspective, recent in vitro studies using human liver microsomes indicate that 7-azaspiro[4.5]decan-10-one exhibits favorable pharmacokinetic properties, with a half-life exceeding 4 hours and minimal CYP450 inhibition. These characteristics, combined with its synthetic accessibility, position this compound as an attractive building block for medicinal chemistry programs. Current research efforts are exploring its application in targeted protein degradation strategies and as a core structure for allosteric modulators.

The pharmaceutical industry has shown increasing interest in 7-azaspiro[4.5]decan-10-one derivatives, with several candidates entering preclinical development. A recent industry report from Evaluate Pharma projects that compounds based on this scaffold could reach the market within 5-7 years, particularly for neurological indications. However, challenges remain in optimizing selectivity and reducing potential off-target effects, which are active areas of current research.

• 42949-24-6(1-Azatricyclo3.3.1.1(3,7)decan-4-one)
• 4629-80-5(1,3-Dimethylpiperidin-4-one)
• 150668-82-9(3,3-Dimethylpiperidin-4-one)
• 3612-16-6(1-Ethyl-3-methylpiperidin-4-one)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)